These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 21412231)
1. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Shram MJ; Schoedel KA; Bartlett C; Shazer RL; Anderson CM; Sellers EM Clin Pharmacol Ther; 2011 May; 89(5):683-92. PubMed ID: 21412231 [TBL] [Abstract][Full Text] [Related]
2. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Smith SR; Prosser WA; Donahue DJ; Morgan ME; Anderson CM; Shanahan WR; Obesity (Silver Spring); 2009 Mar; 17(3):494-503. PubMed ID: 19057523 [TBL] [Abstract][Full Text] [Related]
3. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM; J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446 [TBL] [Abstract][Full Text] [Related]
4. Multicenter, placebo-controlled trial of lorcaserin for weight management. Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR; N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200 [TBL] [Abstract][Full Text] [Related]
5. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. Schoedel KA; Addy C; Chakraborty B; Rosko K; Dunbar S; Maes A; Chen N; Stoch SA; Wagner J; Chodakewitz J; Sellers EM J Clin Psychopharmacol; 2012 Aug; 32(4):492-502. PubMed ID: 22722508 [TBL] [Abstract][Full Text] [Related]
7. Oral ketamine as a positive control in human abuse potential studies. Shram MJ; Sellers EM; Romach MK Drug Alcohol Depend; 2011 Apr; 114(2-3):185-93. PubMed ID: 21109365 [TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of lorcaserin in the management of obesity. Hess R; Cross LB Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762 [TBL] [Abstract][Full Text] [Related]
9. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study. Pirtle JL; Hickman MD; Boinpelly VC; Surineni K; Thakur HK; Grasing KW Pharmacol Biochem Behav; 2019 May; 180():52-59. PubMed ID: 30811963 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456 [TBL] [Abstract][Full Text] [Related]
11. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Hurren KM; Berlie HD Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982 [TBL] [Abstract][Full Text] [Related]
12. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Johnson MW; Suess PE; Griffiths RR Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817 [TBL] [Abstract][Full Text] [Related]
13. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677 [TBL] [Abstract][Full Text] [Related]
14. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423 [TBL] [Abstract][Full Text] [Related]
15. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689 [TBL] [Abstract][Full Text] [Related]
17. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis. Nguyen CT; Zhou S; Shanahan W; Fain R Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931 [TBL] [Abstract][Full Text] [Related]
19. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Nigro SC; Luon D; Baker WL Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263 [TBL] [Abstract][Full Text] [Related]
20. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]